Pfizer’s Talzenna in combi with Xtandi improves survival outcomes in metastatic castration resistant prostate cancer: New York Saturday, February 15, 2025, 11:00 Hrs [IST] Pfize ...

For patients with metastatic castration-resistant prostate cancer (mCRPC) unselected for homologous recombination repair (HRR ...

Pfizer's strong Q4 2024 results showcase growth in cancer drugs and Vyndaqel sales. Learn why PFE stock is a top pick for ...

Results from the company’s Talapro-2 trial saw a 38% reduction in the risk of death among HRR-mutated patients.

Today, Pfizer said that its phase 3 TALAPRO 2 trial of PARP drug Talzenna (talazoparib) in combination with its Astellas-partnered anti-androgen therapy Xtandi (enzalutamide) reduced radiographic ...

The combination showed a 37% reduction in rPFS in an all-comer population when combined with anti-androgen therapy Xtandi (enzalutamide) in the TALAPRO-2 study, and a 55% reduction for patients ...

Karim Fizazi presented the final overall survival results from the TALAPRO-2 trial, which evaluated talazoparib + enzalutamide as first-line treatment for HRR-deficient metastatic castration-resistant ...

Efficacy of Talazoparib and Enzalutamide in mCRPC Patients Previously Treated with Androgen Receptor Pathway Inhibitors or Docetaxel – Post Hoc Analysis from Both Cohorts in TALAPRO-2 Study Neeraj ...